Boundless Bio, Inc., biopharma company, develops therapies and medicines for the treatment of cancers. It offers therapeutics based on extrachromosomal DNA (ecDNA) one of the drivers of the aggressive cancers, such as cancers characterized by high copy number amplification of oncogenes. The company was formerly known as Pretzel Therapeutics, Inc. Boundless Bio, Inc. was founded in 2018 and is based in LA Jolla, California.
Allay Therapeutics offers analgesic products for post-surgical pain management and recuperation. The company was founded in 2017 and is headquartered in Menlo Park, California, United States.
Obsidian Therapeutics develops innovative cell and gene therapies aimed at enhancing adoptive immunotherapy for cancer patients. Founded in 2015 and based in Cambridge, Massachusetts, the company focuses on creating next-generation therapies that utilize pharmacologic operating systems to provide precise control over protein activity within cells. This technology allows for the development of adoptive cell therapies with advanced functionalities that can be managed by physicians using simple, safe, and orally active medications. By offering improved control over treatment, Obsidian Therapeutics aims to provide better outcomes for patients compared to existing cell therapy options.
Sonoma Biotherapeutics develops adoptive Treg cell therapies aimed at treating autoimmune and degenerative diseases. The company employs advanced genome editing and target-specific cell therapy to create therapeutic solutions that promote self-tolerance and mitigate harmful inflammatory responses associated with conditions such as rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, amyotrophic lateral sclerosis, and Alzheimer's disease. Founded in 2019 and headquartered in South San Francisco, California, with an additional office in Seattle, Washington, Sonoma Biotherapeutics combines expertise in Treg biology and proprietary methodologies to advance its therapeutic platform, focusing on developing disease-modifying and potentially curative treatments.
Neuspera Medical Inc. specializes in the development and manufacture of ultra-miniaturized implantable devices designed for neuromodulation therapy, often referred to as "electroceuticals." Utilizing licensed mid-field powering technology, these devices leverage the body as a natural waveguide to deliver energy effectively. Founded in 2013 and based in San Jose, California, Neuspera aims to enhance the quality of life for patients dealing with chronic illnesses by providing less invasive and adaptable treatment options. The company's innovative approach allows for deeper implantation of its devices, offering patients new possibilities in managing their health conditions.
Elevation Oncology, Inc. is a biotechnology company dedicated to creating precision medicines for patients with genomically defined cancers. Founded in 2019 and headquartered in New York, the company focuses on developing targeted therapies that inhibit specific genetic alterations associated with cancer progression. Its lead candidate, seribantumab, is designed to address tumor growth driven by NRG1 fusions and is currently undergoing clinical evaluation in the Phase 2 CRESTONE study, which includes patients with various tumor types exhibiting this genomic alteration. Through its innovative approach, Elevation Oncology aims to enhance treatment options for individuals with solid tumors linked to specific genetic drivers.
Palleon Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs that target glycan-mediated immune regulation to treat cancer and inflammatory diseases. It offers therapeutics to treat cancer and inflammatory diseases. The company also develops drugs for inflammatory diseases, such as autoimmunity and fibrosis. Palleon Pharmaceuticals Inc. was formerly known as Palleon Pharma Inc. and changed its name to Palleon Pharmaceuticals Inc. in February 2017. The company was founded in 2015 and is based in Waltham, Massachusetts.
Elevation Oncology, Inc. is a biotechnology company dedicated to creating precision medicines for patients with genomically defined cancers. Founded in 2019 and headquartered in New York, the company focuses on developing targeted therapies that inhibit specific genetic alterations associated with cancer progression. Its lead candidate, seribantumab, is designed to address tumor growth driven by NRG1 fusions and is currently undergoing clinical evaluation in the Phase 2 CRESTONE study, which includes patients with various tumor types exhibiting this genomic alteration. Through its innovative approach, Elevation Oncology aims to enhance treatment options for individuals with solid tumors linked to specific genetic drivers.
Epirium Bio, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing therapeutics for cardiovascular diseases and metabolic syndrome. Established in 2008, the company has gained insights into mitochondrial biogenesis and function, leading to the discovery of a novel pharmacological approach for treating conditions associated with mitochondrial deficits. Epirium Bio has developed an intellectual property-protected platform of small molecules that represent a new class of therapeutics aimed at stimulating mitochondrial biogenesis and function. Their lead clinical candidate has demonstrated the ability to trigger mitochondrial biogenesis in early human studies and is being developed for various therapeutic areas, with an initial focus on rare diseases, neuromuscular, and neurodegenerative disorders. This innovative approach seeks to provide new treatment options for patients suffering from conditions such as muscular dystrophy.
Cardero Therapeutics is a start-up pharmaceutical company that is developing a novel class of therapeutics that induces the formation of new mitochondria (mitochondrial biogenesis) and enhances mitochondrial function in response to metabolic demand. Chronic depletion of mitochondria, the principal source of cellular ATP, has been directly linked to the progression of heart failure, sarcopenia, and neurodegeneration. Cardero Therapeutics is collaborating with numerous academic medical centers to advance novel drug candidates structurally based on a newly discovered human hormone that appears to fundamentally regulate mitochondrial density and function in all tissues. Cardero Therapeutics believes that enhancing myocyte bioenergetics will comprise an innovative therapeutic approach complementary to currently available cardiovascular drugs. The company’s clinical development focus is the lethal cardiomyopathy associated with orphan diseases characterized by loss of mitochondria in muscle and heart, resulting in heart failure that is poorly responsive to current medical interventions. Initial clinical trials are directed toward Duchenne muscular dystrophy and Friedreich’s ataxia.
BlackThorn Therapeutics operator of a clinical-stage biopharmaceutical company intended to develop precision medicine for disorders of the central nervous system (CNS) based on advances in computational and clinical neuroscience. The company leverages a deep understanding of brain and behavior relationships that seeks to overcome historic challenges in drug discovery and development by targeting dysfunctional brain circuits. Its proprietary computational platform, the company seeks to identify novel targets, small molecule drug candidates and biologically-based patient subgroups most likely to respond to treatment.
Twentyeight-Seven, Inc. is a biotechnology company based in Watertown, Massachusetts, specializing in the development of small molecules that modulate microRNAs (miRNAs) by targeting the proteins that interact with these molecules. Their innovative approach focuses on using short non-coding RNAs to inhibit gene expression, suppress mRNA translation, and promote mRNA decay. By targeting miRNAs that play a critical role in cancer initiation, progression, and metastasis, Twentyeight-Seven aims to create effective therapeutic solutions for cancer treatment.
Nuvaira, Inc. is a medical device company focused on developing innovative treatments for obstructive lung diseases, particularly chronic obstructive pulmonary disease (COPD). The company has created a novel, catheter-based Lung Denervation System designed to address airway nerve hyperactivity, a common issue in patients with COPD and asthma. This minimally invasive procedure targets the parasympathetic nerves of the lungs, aiming to enhance lung function, improve exercise capacity, and elevate the quality of life for affected individuals. Founded in 2008 and headquartered in Minneapolis, Minnesota, Nuvaira was previously known as Holaira, Inc. before rebranding in June 2017.
Earlens is a privately held medical technology company committed to transforming the hearing experience for millions of people who suffer from hearing loss.The company has developed the Earlens Contact Hearing Solution, which directly activates natural hearing, delivering the broadest bandwidth available today and superior sound quality. This revolutionary, non-surgical hearing solution uses a small lens to vibrate the eardrum, replicating the natural hearing process. The Earlens Contact Hearing Solution received FDA clearance in 2019 for a second generation of the Earlens technology. Unlike traditional hearing aids, which are in effect tiny speakers that simply turn up the volume on air conducted sound, the Earlens Contact Hearing Solution™ is the world’s first to deliver sound directly to the eardrum.
Twentyeight-Seven, Inc. is a biotechnology company based in Watertown, Massachusetts, specializing in the development of small molecules that modulate microRNAs (miRNAs) by targeting the proteins that interact with these molecules. Their innovative approach focuses on using short non-coding RNAs to inhibit gene expression, suppress mRNA translation, and promote mRNA decay. By targeting miRNAs that play a critical role in cancer initiation, progression, and metastasis, Twentyeight-Seven aims to create effective therapeutic solutions for cancer treatment.
Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops which stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical need. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.
Obsidian Therapeutics develops innovative cell and gene therapies aimed at enhancing adoptive immunotherapy for cancer patients. Founded in 2015 and based in Cambridge, Massachusetts, the company focuses on creating next-generation therapies that utilize pharmacologic operating systems to provide precise control over protein activity within cells. This technology allows for the development of adoptive cell therapies with advanced functionalities that can be managed by physicians using simple, safe, and orally active medications. By offering improved control over treatment, Obsidian Therapeutics aims to provide better outcomes for patients compared to existing cell therapy options.
Visterra, Inc. is a clinical-stage biopharmaceutical company focused on developing precision antibody-based treatments for difficult-to-treat diseases, particularly infectious diseases. Utilizing its Hierotope platform, Visterra designs monoclonal antibodies such as VIS410, aimed at treating hospitalized patients with influenza A, and VIS513 for Dengue fever. The company is also advancing VIS705, an antibody-drug conjugate for Pseudomonas aeruginosa infections, and VIS649, which targets Immunoglobulin A Nephropathy (IgAN). Founded in 2007 and based in Waltham, Massachusetts, Visterra was previously known as Parasol Therapeutics, Inc. The company operates as a subsidiary of Otsuka America, Inc. and emphasizes innovative therapeutic solutions to address significant unmet medical needs.
Palleon Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs that target glycan-mediated immune regulation to treat cancer and inflammatory diseases. It offers therapeutics to treat cancer and inflammatory diseases. The company also develops drugs for inflammatory diseases, such as autoimmunity and fibrosis. Palleon Pharmaceuticals Inc. was formerly known as Palleon Pharma Inc. and changed its name to Palleon Pharmaceuticals Inc. in February 2017. The company was founded in 2015 and is based in Waltham, Massachusetts.
Earlens is a privately held medical technology company committed to transforming the hearing experience for millions of people who suffer from hearing loss.The company has developed the Earlens Contact Hearing Solution, which directly activates natural hearing, delivering the broadest bandwidth available today and superior sound quality. This revolutionary, non-surgical hearing solution uses a small lens to vibrate the eardrum, replicating the natural hearing process. The Earlens Contact Hearing Solution received FDA clearance in 2019 for a second generation of the Earlens technology. Unlike traditional hearing aids, which are in effect tiny speakers that simply turn up the volume on air conducted sound, the Earlens Contact Hearing Solution™ is the world’s first to deliver sound directly to the eardrum.
Moximed, Inc. is focused on developing joint-preserving solutions for patients suffering from knee osteoarthritis. The company's primary product, the Atlas System, functions as an implantable joint unloader, similar to a shock absorber, specifically targeting individuals experiencing pain in the medial compartment of the knee. This innovative approach aims to alleviate joint pain, reduce dynamic load, and potentially delay the necessity for more invasive surgical interventions. Moximed seeks to enhance the standard of care for osteoarthritis patients, helping them maintain an active lifestyle while serving both patients and medical professionals globally. Established in 2006 and headquartered in Hayward, California, Moximed was previously known as ExploraMed NC4, Inc.
Innoventure is a startup medical device accelerator which brings US/EU medtech assets to China and get through the local regulatory path to develop further value.
Earlens is a privately held medical technology company committed to transforming the hearing experience for millions of people who suffer from hearing loss.The company has developed the Earlens Contact Hearing Solution, which directly activates natural hearing, delivering the broadest bandwidth available today and superior sound quality. This revolutionary, non-surgical hearing solution uses a small lens to vibrate the eardrum, replicating the natural hearing process. The Earlens Contact Hearing Solution received FDA clearance in 2019 for a second generation of the Earlens technology. Unlike traditional hearing aids, which are in effect tiny speakers that simply turn up the volume on air conducted sound, the Earlens Contact Hearing Solution™ is the world’s first to deliver sound directly to the eardrum.
Visterra, Inc. is a clinical-stage biopharmaceutical company focused on developing precision antibody-based treatments for difficult-to-treat diseases, particularly infectious diseases. Utilizing its Hierotope platform, Visterra designs monoclonal antibodies such as VIS410, aimed at treating hospitalized patients with influenza A, and VIS513 for Dengue fever. The company is also advancing VIS705, an antibody-drug conjugate for Pseudomonas aeruginosa infections, and VIS649, which targets Immunoglobulin A Nephropathy (IgAN). Founded in 2007 and based in Waltham, Massachusetts, Visterra was previously known as Parasol Therapeutics, Inc. The company operates as a subsidiary of Otsuka America, Inc. and emphasizes innovative therapeutic solutions to address significant unmet medical needs.
Kona Medical, Inc. is a medical technology company based in Issaquah, Washington, founded in 2009 by Dr. Michael Gertner. The company specializes in developing a non-invasive ultrasound-based therapy system aimed at treating hypertension and related disorders. Its primary product, Surround Sound, is a hypertension therapy system that employs ultrasound imaging to precisely deliver focused ultrasound energy for renal denervation. This innovative approach targets the nerves associated with kidney function, offering a less invasive alternative for patients suffering from drug-resistant hypertension. By leveraging advancements in therapeutic focused ultrasound, Kona Medical seeks to improve treatment efficacy and reduce the health risks associated with high blood pressure.
Moximed, Inc. is focused on developing joint-preserving solutions for patients suffering from knee osteoarthritis. The company's primary product, the Atlas System, functions as an implantable joint unloader, similar to a shock absorber, specifically targeting individuals experiencing pain in the medial compartment of the knee. This innovative approach aims to alleviate joint pain, reduce dynamic load, and potentially delay the necessity for more invasive surgical interventions. Moximed seeks to enhance the standard of care for osteoarthritis patients, helping them maintain an active lifestyle while serving both patients and medical professionals globally. Established in 2006 and headquartered in Hayward, California, Moximed was previously known as ExploraMed NC4, Inc.
Twelve manufactures medical devices. It was formerly known as Foundry Newco XII, Inc. The company was incorporated in 2009 and is based in Menlo Park, California.
Visterra, Inc. is a clinical-stage biopharmaceutical company focused on developing precision antibody-based treatments for difficult-to-treat diseases, particularly infectious diseases. Utilizing its Hierotope platform, Visterra designs monoclonal antibodies such as VIS410, aimed at treating hospitalized patients with influenza A, and VIS513 for Dengue fever. The company is also advancing VIS705, an antibody-drug conjugate for Pseudomonas aeruginosa infections, and VIS649, which targets Immunoglobulin A Nephropathy (IgAN). Founded in 2007 and based in Waltham, Massachusetts, Visterra was previously known as Parasol Therapeutics, Inc. The company operates as a subsidiary of Otsuka America, Inc. and emphasizes innovative therapeutic solutions to address significant unmet medical needs.
Ivantis Inc. is dedicated to developing innovative treatments for primary open angle glaucoma, a condition affecting over 60 million people globally. The company has created an intracanalicular scaffold or implantable device designed to alleviate high intraocular pressure in patients, offering a less invasive and more effective therapeutic option. Founded in 2007 and based in Irvine, California, Ivantis also provides a Session Persistence Server, which safeguards telnet task workers against data loss due to network issues and ensures terminal emulation users maintain productivity across various devices and operating systems. As Ivantis advances its glaucoma treatment solutions, it aims to expand its focus to other debilitating ophthalmic diseases. The company primarily serves ophthalmology specialists in the United States, providing its solutions for use in clinical trials.
Nuvaira, Inc. is a medical device company focused on developing innovative treatments for obstructive lung diseases, particularly chronic obstructive pulmonary disease (COPD). The company has created a novel, catheter-based Lung Denervation System designed to address airway nerve hyperactivity, a common issue in patients with COPD and asthma. This minimally invasive procedure targets the parasympathetic nerves of the lungs, aiming to enhance lung function, improve exercise capacity, and elevate the quality of life for affected individuals. Founded in 2008 and headquartered in Minneapolis, Minnesota, Nuvaira was previously known as Holaira, Inc. before rebranding in June 2017.
Sensimed AG is a medical devices company based in Lausanne, Switzerland, founded in 2003. The company specializes in the design, development, and commercialization of integrated micro-systems for medical applications, particularly focusing on glaucoma management. Its flagship product, the SENSIMED Triggerfish, is a soft, single-use contact lens that enables continuous monitoring of intraocular pressure (IOP) fluctuations in glaucoma patients over a 24-hour period. The Triggerfish system includes disposable sensors, an adhesive antenna for communication, a battery-powered recorder for data collection, and software for data management and analysis. Sensimed aims to enhance personalized treatment for glaucoma patients by analyzing the collected data to identify pathological patterns and improve clinical outcomes. The company's products are distributed through partners across Europe, Asia-Pacific, the Middle East, and the Americas. As of December 2019, Sensimed operates as a subsidiary of SEED Co., Ltd.